Browsing by Author Buse, John B.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2014Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialNeal, Bruce; Buse, John B.; et al, .; Henry, Robert; Lincoff, A. Michael; Malmberg, Klas; Nicholls, Stephen; Ryden, Lars; Schwartz, Gregory; Tardif, Jean-Claude; Wedel, Hans; The George Institute for Global HealthEffect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial, JAMA, vol.311, 15, 2014,pp 1515-1525
2010Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular EventsFulcher, Greg; Belenkov, Yuri; Bethel, M. Angelyn; Boolell, Mitradev; Buckley, Brendan M.; Buse, John B.; Chacra, Antonio R.; et al, various; Haffner, Steven; Holman, Rury R.; Holzhauer, Björn; Hua, Tsushung A.; McMurray, John J.V.; Northern Clinical School: MedicineEffect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events, New England Journal of Medicine, vol.362, 16,pp 1463-1476
2010Effect of Valsartan on the Incidence of Diabetes and Cardiovascular EventsFulcher, Greg; Belenkov, Yuri; Bethel, M. Angelyn; Boolell, Mitradev; Buckley, Brendan M.; Buse, John B.; Chacra, Antonio R.; et al, various; Haffner, Steven; Holman, Rury R.; Holzhauer, Björn; Hua, Tsushung A.; McMurray, John J.V.; Northern Clinical School: MedicineEffect of Valsartan on the Incidence of Diabetes and Cardiovascular Events, New England Journal of Medicine, vol.362, 16,pp 1477-1490
2017Effects of sotagliflozin added to insulin in patients with type 1 diabetesFulcher, Greg; Banks, Phillip; Buse, John B.; Danne, Thomas; Davies, Melanie; Garg, Satish K.; Gesty-Palmer, Diane; Henry, Robert R.; Kushner, Jake A.; Lapuerta, Pablo; Mcguire, Darren K; Peters, Anne; Pozzilli, Paolo; Simo, Raphael; Strumph, Paul; Northern Clinical School: MedicineEffects of sotagliflozin added to insulin in patients with type 1 diabetes, New England Journal of Medicine, vol.377, 24, 2017,pp 2337-2348
2013Evaluation of the dual peroxisome proliferator-activated receptor a/y agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trialNeal, Bruce; Buse, John B.; et al, Various; Henry, Robert; Lincoff, A. Michael; Malmberg, Klas; Nicholls, Stephen; Ryden, Lars; Schwartz, Gregory; Tardif, Jean-Claude; Wedel, Hans; Weichert, Arlette; The George Institute for Global HealthEvaluation of the dual peroxisome proliferator-activated receptor a/y agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial, American Heart Journal, vol.166, 3, 2013,pp 429-434.e1
2009International Expert Committee report on the role of the A1C assay in the diagnosis of diabetesColagiuri, Stephen; Balkau, Beverley; Bonora, Enzo; Borch-Johnsen, Knut; Buse, John B.; Davidson, Mayer B.; Defronzo, Ralph Albarado; et al, various; Genuth, Saul M.; Holman, Rury R.; Ji, Linong; Nathan, David M; Central Clinical School: MedicineInternational Expert Committee report on the role of the A1C assay in the diagnosis of diabetes, Diabetes Care, vol.32,(7),2009,pp 1327-1334